Key Stats for Gilead Sciences Stock
- This-Week Performance: 4%
- 52-week Range: $93 to $142
- Valuation Model Target Price: $152
- Implied Upside: 7.2% over 1.9 years
Value your favorite stocks like Gilead Sciences with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Gilead Sciences stock rose about 4% this week, trading higher across most sessions and finishing near the upper end of its recent range. The move developed steadily through the week, reflecting improving sentiment rather than a reaction to a single headline.
The move was driven by renewed buying tied to confidence in Gilead’s earnings durability and oncology outlook, particularly expectations that Trodelvy can contribute more meaningfully to future revenue.
As investors reassessed the company’s growth mix alongside stable, high-margin cash flow from its HIV franchise, demand improved while selling pressure remained limited.
Analyst activity reinforced that momentum, with several firms having raised or reaffirmed price targets in recent updates that remained top of mind this week.
TD Cowen increased its target to $145 from $125, JPMorgan lifted its target to $150, and Citigroup raised its target to $156, citing pipeline visibility and earnings stability.
The accumulation of upward revisions helped support buying interest even without a single new upgrade headline.
Looking ahead, attention is centered on upcoming earnings and further clinical and regulatory updates.
With shares now trading near the upper end of their recent range, this week’s move reflects confidence in execution and forward visibility rather than short-term speculation.
See analysts’ growth forecasts and price targets for Gilead Sciences (It’s free) >>>
Is Gilead Sciences Undervalued?
Under valuation model assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 3.2%
- Operating Margins: 47.2%
- Exit P/E Multiple: 15.0x
Based on these inputs, the model estimates a target price of $152, implying 7.2% total upside from recent levels over the next 1.9 years.
Over the next year, results are likely shaped by how consistently oncology revenue scales, particularly as Trodelvy advances further into later lines of treatment and becomes a more meaningful contributor to total sales.
Gilead’s HIV portfolio continues to anchor earnings, generating strong cash flow that supports pipeline investment without pressuring margins or the balance sheet.
As business mix improves and oncology contribution grows, returns appear more execution-driven than valuation-driven.
Gilead appears undervalued at current levels, with upside supported by stable earnings, improving mix, and clearer visibility into longer-term growth drivers.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
